BridgeBio Oncology Therapeutics stock analysis
Want to see BBOT full AI Analyst Report?
BridgeBio Oncology Therapeutics (BBOT) Stock Price & Analysis
BBOT Stock Chart & Stats
- Day’s Range
- $1.79 - $1.94
- 52-Week Range
- $1.79 - $14.87
- Previous Close
- $1.86
- Volume
- N/A
- Average Volume (3M)
- 632.75K
- Market Cap
- $149.27M
- Enterprise Value
- $137.27M
- Total Cash (Recent Filing)
- $193.87M
- Total Debt (Recent Filing)
- $2.38M
- Price to Earnings (P/E)
- ―
- Beta
- 0.84
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.44
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Minimal Leverage
Minimal debt reduces interest burden and financial obligations while preserving flexibility to fund research internally. The conservative capital structure may help BBOT extend its operating runway and withstand funding pressure better than a highly leveraged biotechnology company.
Asset Base And Liquidity Runway
A sizable asset base relative to the company’s minimal debt provides a financial cushion while BBOT advances its oncology pipeline. This does not remove funding risk, but it can support continued research activity and reduce dependence on immediate borrowing.
Cash-Backed Losses
Losses that closely track negative free cash flow indicate that reported weakness is largely reflected in actual cash usage rather than being obscured by large non-cash charges. That transparency improves assessment of the business model and future funding needs.
Bears Say
No Revenue
The absence of revenue means BBOT has not yet demonstrated commercial product traction or an operating revenue base to fund research. Until sales begin, progress remains dependent on capital resources and successful development of oncology therapeutics.
Widening Losses
Losses have expanded materially over multiple reporting periods, showing that investment requirements are increasing faster than any demonstrated operating income. Persistent losses reduce financial flexibility and make future equity funding or asset use more consequential.
Accelerating Cash Burn
The sharp negative cash flow indicates that BBOT is consuming substantial cash to operate and develop its business. If this burn persists, the company may need to rely on its asset base or raise additional capital before reaching commercial self-sufficiency.
BridgeBio Oncology Therapeutics News
Analyst Maintains Buy Rating on BridgeBio Oncology Therapeutics, Reaffirming Unchanged $23 Price Target Ahead of Key 2026 KRAS Data Catalysts
John Newman, an analyst from Canaccord Genuity, reiterated the Buy rating on BridgeBio Oncology Therapeutics. The associated price target remains the same with $23.00. John Newman has given his Buy
BridgeBio Oncology Therapeutics: Buy Rating Reiterated as BBO‑10203 Value Catalysts Highlighted; Price Target Maintained at $23
Analyst John Newman of Canaccord Genuity maintained a Buy rating on BridgeBio Oncology Therapeutics, retaining the price target of $23.00. John Newman’s rating is based on the upcoming value catalysts
Analyst Initiates Buy on BridgeBio Oncology, Sees Significant Upside With $27 Price Target Amid Promising KRAS and PI3Kα Precision Oncology Pipeline
BridgeBio Oncology Therapeutics (BBOT) has received a new Buy rating, initiated by J.P. Morgan analyst, . Analyst has given his Buy rating due to a combination of factors, primarily the
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
What is BridgeBio Oncology Therapeutics’s market cap?
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
Is BridgeBio Oncology Therapeutics overvalued?
Does BridgeBio Oncology Therapeutics pay dividends?
What is BridgeBio Oncology Therapeutics’s EPS estimate?
How many shares outstanding does BridgeBio Oncology Therapeutics have?
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
BridgeBio Oncology Therapeutics Stock Smart Score
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pedro J. Beltran
- Employees
- 84
- Website
- bbotx.com
- Address
- 256 E. Grand Avenue, South San Francisco, CA, 94080, US
BridgeBio Oncology Therapeutics (BBOT) Earnings & Revenues
BBOT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |










